Successful Treatment of Congenital Erythroleukemia With Low-Dose Cytosine Arabinoside

We report a term male with congenital acute erythroleukemia who achieved sustained remission with low-dose cytosine arabinoside alone

Authors:
Halliday GC, O'Reilly J, Kelsey C, Cole CH, Kotecha RS.

Authors notes:
Pediatric Blood and Cancer. 2016;63(3):566-7.

Keywords:
Treatment, Congenital Erythroleukemia, Low-Dose, Cytosine Arabinoside, Oncology, Pediatric Cancer, Acute myeloid leukemia, Ara-C

Abstract:

Congenital leukemia is rare, accounting for less than 1% of childhood leukemia. Acute myeloid leukemia (AML) occurs more frequently than acute lymphoblastic leukemia during the first four weeks of life, with acute monoblastic leukemia accounting for approximately 50% of cases, followed by acute myelomonocytic leukemia in 20%. Acute erythroleukemia is extremely rare, with six reported cases. We report a term male with congenital acute erythroleukemia who achieved sustained remission with low-dose cytosine arabinoside (Ara-C) alone.